[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334906-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334906-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exosomes-as-drug-delivery-systems-in-glioma-immunotherapy","Exosomes as drug delivery systems in glioma immunotherapy","","Cancer immunotherapy has shown substantial benefits across many cancers, yet glioma outcomes remain limited due to constrained drug delivery and insufficient immune activation. Exosomes function as drug carriers with low toxicity, good biocompatibility, and natural cell targeting, potentially improving therapeutic efficacy. This review addresses current challenges in glioma immunotherapy, discusses exosome-based preparation and application strategies to enhance immunogenicity and reverse immunosuppressive tumor microenvironments, and outlines obstacles for clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exosomes-as-drug-delivery-systems-in-glioma-immunotherapy/334906/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exosomes-as-drug-delivery-systems-in-glioma-immunotherapy/334906.png","ImageObject",300,407,{"name":42,"@type":43},"Violet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is glioma immunotherapy less effective than immunotherapy for other cancers?","Question",{"text":63,"@type":64},"Glioma immunotherapy benefits are limited by restricted therapeutic delivery across the blood–brain barrier, glioma’s low immunogenicity, and an immunosuppressive tumor microenvironment that inhibits effector T-cell activity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What advantages do exosomes provide as drug carriers for glioma immunotherapy?",{"text":68,"@type":64},"Exosomes offer low toxicity, good biocompatibility, and intrinsic cell targeting, which can enhance glioma immunotherapy efficacy by improving delivery and interaction with relevant cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review cover regarding exosome-based systems?",{"text":72,"@type":64},"It introduces problems in glioma immunotherapy, explains how exosomes address them, and discusses preparation and application strategies—especially approaches that enhance immunogenicity and counter the immunosuppressive tumor microenvironment—along with challenges in clinical translation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334906,1790239313,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Hao et al. Journal of Nanobiotechnology (2024) 22:340  \n[https://doi.org/10.1186/s12951-024-02611-4](https://doi.org/10.1186/s12951-024-02611-4)  \nJournal of Nanobiotechnology  \nREVIEW Open Access  \nExosomes as drug delivery systems in glioma immunotherapy  \nXinqing Hao 1,2, Shiming Wang3, Liang Wang 1,2, Jiaqi Li4, Ying Li 1,2* and Jing Liu 1,2*  \nAbstract  \nRecently, the significant benefits of cancer immunotherapy for most cancers have been demonstrated in clinical and preclinical studies. However, the efficacy of these immunotherapies for gliomas is limited, owing to restricted drug delivery and insufficient immune activation. As drug carriers, exosomes offer the advantages of low toxicity, good biocompatibility, and intrinsic cell targeting, which could enhance glioma immunotherapy efficacy. However, a review of exosome-based drug delivery systems for glioma immunotherapy has not been presented. This review introduces the current problems in glioma immunotherapy and the role of exosomes in addressing these issues. Meanwhile, preparation and application strategies of exosome-based drug delivery systems for glioma immunotherapy are discussed, especially for enhancing immunogenicity and reversing the immunosuppressive tumor microenvironment. Finally, we briefly describe the challenges of exosome-based drug delivery systems in clinical translation. We anticipate that this review will guide the use of exosomes as drug carriers for glioma immunotherapy.  \n*Correspondence: Ying Li[liying_xx@163.com](liying_xx@163.com)[ ](liying_xx@163.com)Jing Liu [liujing@dmu.edu.cn](liujing@dmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nGraphical Abstract  \nKeywords Exosomes, Glioma, Drug delivery systems, Immunotherapy  \nIntroduction  \nGliomas are tumors derived from glial or neural precursor cells in the central nervous system (CNS), including astrocytoma, oligodendroglioma, ventricular meningioma, and mixed glioma. According to recent data from The Central Brain Tumor Registry of the United States, gliomas account for 24% of all CNS tumors and 80.9% of malignant tumors, making them the most prevalent intracranial malignancy [1]. The World Health Organization categorizes gliomas into four grades (grades 1–4), with grades 1–2 considered low-grade gliomas and grades 3–4 classified as high-grade gliomas [2]. Lowgrade gliomas are associated with a 10-year survival rate of 39% and a median survival time of 87.3 months [3]. Conversely, high-grade gliomas, particularly glioblastoma (GBM), demonstrate high malignancy, with a median survival time not exceeding 15 months [4]. Owing to their high recurrence rate, high disability and mortality rates, and limited cure rate, gliomas are the most aggressive and refractory CNS tumors. Currently, the standard  \ntreatment","cbCaifkvT8UMVR0K","https://ap.wps.com/l/cbCaifkvT8UMVR0K","pdf",7075965,25,"English","# Abstract\n# Introduction\n## Challenges in glioma immunotherapy\n## Tumor immune cycle and immunotherapies\n## Need for targeted drug delivery","[{\"question\":\"Why is glioma immunotherapy less effective than immunotherapy for other cancers?\",\"answer\":\"Glioma immunotherapy benefits are limited by restricted therapeutic delivery across the blood–brain barrier, glioma’s low immunogenicity, and an immunosuppressive tumor microenvironment that inhibits effector T-cell activity.\"},{\"question\":\"What advantages do exosomes provide as drug carriers for glioma immunotherapy?\",\"answer\":\"Exosomes offer low toxicity, good biocompatibility, and intrinsic cell targeting, which can enhance glioma immunotherapy efficacy by improving delivery and interaction with relevant cells.\"},{\"question\":\"What does the review cover regarding exosome-based systems?\",\"answer\":\"It introduces problems in glioma immunotherapy, explains how exosomes address them, and discusses preparation and application strategies—especially approaches that enhance immunogenicity and counter the immunosuppressive tumor microenvironment—along with challenges in clinical translation.\"}]","Exosomes as drug delivery systems in glioma immunotherapy | PDF",1790008796,63]